191 related articles for article (PubMed ID: 25608713)
1. The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy.
Coughlan M; Elstrom R
Cancer Imaging; 2014 Nov; 14(1):34. PubMed ID: 25608713
[TBL] [Abstract][Full Text] [Related]
2. Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma.
Mylam KJ; Nielsen AL; Pedersen LM; Hutchings M
PET Clin; 2014 Oct; 9(4):443-55, vi. PubMed ID: 26050946
[TBL] [Abstract][Full Text] [Related]
3. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD
Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542
[TBL] [Abstract][Full Text] [Related]
4. FDG-PET for Early Response Assessment in Lymphomas: Part 2-Diffuse Large B-Cell Lymphoma, Use of Quantitative PET Evaluation.
Cheson BD; Kostakoglu L
Oncology (Williston Park); 2017 Jan; 31(1):71-76. PubMed ID: 28090627
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis.
Burggraaff CN; de Jong A; Hoekstra OS; Hoetjes NJ; Nievelstein RAJ; Jansma EP; Heymans MW; de Vet HCW; Zijlstra JM
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):65-79. PubMed ID: 30141066
[TBL] [Abstract][Full Text] [Related]
6. Interim FDG PET/CT as a prognostic factor in diffuse large B-cell lymphoma.
Fuertes S; Setoain X; Lopez-Guillermo A; Carrasco JL; Rodríguez S; Rovira J; Pons F
Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):496-504. PubMed ID: 23344136
[TBL] [Abstract][Full Text] [Related]
7. The role of FDG-PET in the interim evaluation of therapy response in diffuse large B-cell lymphoma.
Ellmann A
Transfus Apher Sci; 2013 Aug; 49(1):40-2. PubMed ID: 23769694
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
[TBL] [Abstract][Full Text] [Related]
9. [The outcome of whole-body FDG-PET examination predicts the future of patients with diffuse large-cell lymphoma in the use of both intermediary staging and at the end of standard chemotherapy].
Trnený M; Belohlávek O; Koren J; Pytlík R; Sálková J; Klener P
Vnitr Lek; 2007 Sep; 53(9):936-41. PubMed ID: 18019661
[TBL] [Abstract][Full Text] [Related]
10. Prognostic nomogram for diffuse large B-cell lymphoma incorporating the International Prognostic Index with interim-positron emission tomography findings.
Chow A; Phillips M; Siew T; Cull G; Augustson B; Ward M; Joske D
Intern Med J; 2013 Aug; 43(8):932-9. PubMed ID: 23692386
[TBL] [Abstract][Full Text] [Related]
11. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.
Safar V; Dupuis J; Itti E; Jardin F; Fruchart C; Bardet S; Véra P; Copie-Bergman C; Rahmouni A; Tilly H; Meignan M; Haioun C
J Clin Oncol; 2012 Jan; 30(2):184-90. PubMed ID: 22162590
[TBL] [Abstract][Full Text] [Related]
12. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
13. Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients.
Roland V; Bodet-Milin C; Moreau A; Gastinne T; Mahé B; Dubruille V; Maisonneuve H; Juge-Morineau N; Moreau P; Jardel H; Planche L; Mohty M; Moreau P; Harousseau JL; Kraeber-Bodéré F; Le Gouill S
Bone Marrow Transplant; 2011 Mar; 46(3):393-9. PubMed ID: 20577223
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic value of (18)F-FDG PET/CT after first-line treatment in patients with diffuse large B cell lymphoma].
Ying ZT; Wang XJ; Song YQ; Zheng W; Wang XP; Xie Y; Lin NJ; Tu MF; Ping LY; Liu WP; Deng LJ; Zhang C; Yang Z; Zhu J
Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):810-3. PubMed ID: 23384899
[TBL] [Abstract][Full Text] [Related]
15. Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy.
Dickinson M; Hoyt R; Roberts AW; Grigg A; Seymour JF; Prince HM; Szer J; Ritchie D
Br J Haematol; 2010 Jul; 150(1):39-45. PubMed ID: 20507301
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
[TBL] [Abstract][Full Text] [Related]
17. End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma.
Kostakoglu L; Nowakowski GS
PET Clin; 2019 Jul; 14(3):307-315. PubMed ID: 31084771
[TBL] [Abstract][Full Text] [Related]
18. Comparison Between Different PET and CT-Based Imaging Interpretation Criteria at Interim Imaging in Patients With Diffuse Large B-Cell Lymphoma.
Baratto L; Davidzon GA; Moghbel M; Hatami N; Iagaru A; Mittra ES
Clin Nucl Med; 2018 Jan; 43(1):1-8. PubMed ID: 29076913
[TBL] [Abstract][Full Text] [Related]
19. [The role of PET/CT investigation in the management of patients with diffuse large B-cell lymphoma].
Paksi M; Demeter J; Szabó P
Magy Onkol; 2016 Jun; 60(2):108-17. PubMed ID: 27275637
[TBL] [Abstract][Full Text] [Related]
20. Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma.
Wu X; Pertovaara H; Korkola P; Vornanen M; Järvenpää R; Dastidar P; Eskola H; Kellokumpu-Lehtinen PL
Acta Oncol; 2014 Aug; 53(8):1093-9. PubMed ID: 24960581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
